An evaluation of six placebo-controlled clinical trials with one,134 complete individuals concluded that cannabinoids (nabiximols, dronabinol, and THC/CBD) were being connected to a larger common advancement over the Ashworth scale for spasticity in many sclerosis clients compared with placebo, Despite the fact that this did not reach statistical s